PubMed HealthSearch

SEARCH · PubMed Health

Results for “Receptors, Opioid”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 19 recordsLinked to original sources

A new method for receptor autoradiography: [3H]opioid receptors in rat brain.

Opioid receptors can be labeled with [3H]ligands in lightly fixed tissue sections mounted on microscope slides. The preparation of these sections does not seem to alter any of the known characteristics of opioid receptors. The light microscopic autoradiographic distribution of these binding sites can be observed if one attaches emulsion-coated coverslips to these slides to obtain autoradiograms. The distribution of [3H]diprenorphine binding sites determined by this in vitro method is identical to the distribution found in earlier studies utilizing in vivo labeling of opioid receptors. In addition, [3H]opioid peptide binding sites and [3H]dihydromorphine binding sites may be similar, perhaps identical, to those for [3H]diprenorphine, an opiate antagonist. This method has several important advantages over earlier methods for determining the autoradiographic localization of receptors. It is possible, by washing, to reduce nonspecific binding to low levels. Since receptor labeling is performed with single tissue sections mounted on slides, one can examine different receptors in different but adjacent sections. One can use ligands that are not entirely suitable for in vivo labeling (For example, one can use [3H]peptides which do not normally cross the blood-brain barrier). One can perform autoradiographic studies after labeling tissues under a wide variety of conditions (For example, one can examine the effects of various ions and nucleotides on ligand binding distributions). This technique seems to be free of various artifacts, such as edge artifacts, which were common by techniques used in our laboratory earlier. Since one does not have to load an entire animal with radioactive ligand as one must with in vivo labeling, this approach is economically advantageous. One can use postmortem tissues, including that from humans to study receptor distribution with a high anatomical resolution.

Animals

Structure-Function Analysis of the Benzyloxy Moiety of the Delta-Opioid Receptor Positive Modulator BMS-986187: Identification of a Derivative with High Selectivity for the Delta-Opioid Receptor over the Mu-Opioid Receptor In Vitro and In Vivo.

Positive allosteric modulators (PAMs) of the delta-opioid receptor (DOR) enhance endogenous opioid signaling while avoiding the convulsant liability of orthosteric agonists. However, the prototypical DOR-PAM, BMS-986187, also potentiates mu-opioid receptor (MOR) signaling, raising concerns regarding respiratory depression and abuse liability. Here, we report a structure-activity study of the benzyloxy moiety of BMS-986187 to improve selectivity for DOR over MOR, while retaining DOR-PAM potency. Fifty-two new analogues and 12 previously reported ones featuring mono- and disubstitution of the benzyl ring and phenyl-heterocycle replacements were synthesized and evaluated in β-arrestin2 recruitment assays. Ortho-substituted derivatives consistently enhanced DOR-PAM potency, although often increased MOR-PAM activity. One pyridyl derivative (compound 35) retained high DOR-PAM potency and efficacy (EC50 = 0.1 μM, Emax = 91%) with no detectable MOR activity. In mice, compound 35 enhanced DOR-mediated reversal of nitroglycerin-induced hyperalgesia, an effect absent in DOR-knockout mice, without enhancing MOR-mediated antinociception, demonstrating in vivo selectivity.

Receptors, Opioid, delta

Differential impacts of exon 1-associated and exon 11-associated variants of the rat mu opioid receptor gene, Oprm1, on buprenorphine- and morphine-induced analgesia and respiratory depression in male rats.

Buprenorphine has long been recognized as a mu opioid agonist with a distinctive and intricate pharmacological profile. It is a partial agonist at the mu opioid receptor, an antagonist at the kappa and delta opioid receptors, and an agonist at the nociception opioid receptor. Similar to other mu agonists such as morphine and fentanyl, buprenorphine can produce side effects, including tolerance, physical dependence, respiratory depression, and addiction. The mu opioid receptor gene, OPRM1, undergoes extensive alternative splicing, generating an array of splice variants or isoforms, which are conserved from rodents to humans. These splice variants can be categorized into 2 main types, exon 1 (E1)-associated variants and exon 11 (E11)-associated variants. E1-associated variants primarily consist of full-length, 7-transmembrane C-terminal variants, whereas E11-associated variants are typically truncated 6-transmembrane variants. Previous studies established that buprenorphine analgesia in mice is dependent on both E1- and E11-associated variants. However, the role of these variants in buprenorphine analgesia and respiratory depression in rats remains unclear. In this study, we used CRISPR/Cas9 technology to develop 2 rat Oprm1 gene-targeting models in which E1- and E11-associated variants were selectively disrupted, aiming to investigate their roles in buprenorphine and morphine's actions. The results showed that both E1- and E11-associated variants are essential for buprenorphine's analgesic and respiratory depressional effects in rats, whereas morphine's effects are solely attributed to the E1-associated variants. These findings provide new and important insights into the distinct contributions of the E1- and E11-associated variants to the pharmacological actions of buprenorphine and morphine. SIGNIFICANCE STATEMENT: Differential dependences of buprenorphine and morphine analgesia and respiratory depression on Oprm1 exon 1- and exon 11-associated variants revealed in rat gene-targeting models provide new and important insights into unique contributions of these variants to buprenorphine and morphine actions.

Animals

Delta-opioid-receptor activation by [D-Pen2,D-Pen5]enkephalin and morphine inhibits substance P release from trigeminal nucleus slices.

The release of substance P (SP) from spinal dorsal horn slices is partially inhibited by micromolar concentrations of selective delta-opioid receptor agonists. In the present study, we have examined the effect of nanomolar concentrations of [D-Pen2,D-Pen5]enkephalin (DPDPE, delta-opioid receptor agonist) and low micromolar of concentrations morphine on K(+)-evoked SP release from rat trigeminal nucleus caudalis (TNC) slices. DPDPE and morphine inhibited SP release with an apparent maximal effect at 3 nM and at 3 microM, respectively. DPDPE and morphine produced U-shaped concentration-response curves that were completely autoinhibited at 100 nM DPDPE and 1 microM morphine. The inhibition of SP release produced by 3 nM DPDPE and 3 microM morphine was blocked by the opioid receptor antagonists naloxone (30 nM; non-selective) and ICI 174,864 (0.3 microM; delta-selective) but not by nor-binaltorphimine (3 nM n-BNI; kappa-selective), naloxonazine (1 nM; micro 1-selective) or beta-funaltrexamine (20 nM beta-FNA; mu-selective). These findings indicate that delta-opioid receptor-mediated inhibition of SP release from TNC can be achieved by nanomolar concentrations of selective delta-opioid receptor agonists. Activation of delta-opioid receptors by morphine might be involved in the residual analgesia observed after mu 1-opioid receptor blockade and in the analgesia produced by high doses of morphine.

Analgesics

[Effect of opioid receptor blockade with naloxone on plasma renin activity and aldosterone levels in patients with kidney transplantation].

Function of the renin-angiotensin-aldosterone (RAA) system in kidney transplant patients (KTP) is often abnormal as in patients with chronic renal failure. On the other hand the importance of opioids in the regulation of function of endocrine organs is well established. These facts were the background of studies presented in this paper. They aimed to assess the role of opioid receptors in the regulation of the RAA in KTP. 12 patients with a stabilized renal graft function and on cyclosporin A + prednisone therapy and 15 healthy subjects were examined. In all subjects plasma renin activity (PRA), plasma aldosterone level (Ald) and blood pressure were assessed during a 4 hr bed-rest test. In each subject two tests were performed: the first one without naloxone administration, and the second one--after opioid receptor blockade. In KTP significantly elevated PRA and blood pressure and moderately elevated plasma Ald levels were found as compared with normals. After a 4 hr bed rest without naloxone no significant changes of the above mentioned parameters were noticed both in the patients and the controls. After opioid receptors blockade by naloxone a significant decrease of PRA and plasma Ald was observed in both examined groups. This decrease was significantly more marked in KTP than in controls. In addition only in KTP 4 hrs after naloxone administration a significant increase of systolic and diastolic blood pressure was found. Results obtained in this study suggest, that opioid receptors are involved in the regulation of the activity of the RAA system and of blood pressure more markedly in KTP than in healthy subjects.

Adult

Chloroxymorphamine, and opioid receptor site-directed alkylating agent having narcotic agonist activity.

Chloroxymorphamine, the 6beta-N,N-bis(2-chloroethyl) derivative of oxymorphone, is a potent nonequilibrium narcotic agonist in the longitudinal muscle preparation of guinea pig ileum. The corresponding naltrexone analog,chlornaltrexamine, is a potent nonequilibrium antagonist of morphine. These receptor sitedirected alkylating agents possess considerable potenial as pharmacologic and biochemical probes of apoid receptors.

Alkylating Agents

Endogenous opioid peptides: multiple agonists and receptors.

Opioid peptides were assayed by inhibition of 3H-naloxone and 3H-leu-enkephalin binding in brain homogenates and by depression of contractions of the guinea pig ileum and mouse vas deferens. We conclude that the opioid peptidergic system has agonists of different characteristics which interact with more than one type of receptor.

Animals

The hedonic impact of cleaner-client fish interactions is mediated by the opioid system.

According to the 'incentive salience hypothesis' reward processing involves two main components, including the motivation to obtain a reward (i.e. incentive salience or 'wanting') and the hedonic pleasure felt during its consumption (i.e. hedonic impact or 'liking'), which are dissociable. The processing of these hedonic mechanisms is suggested to be mediated by opioid neurotransmission; however, most evidence comes from humans and other mammals. Here we argue that, in mutualistic associations, client fish seek to interact with cleaner fish not only due to the immediate benefits of being cleaned but also because of the hedonic impact of tactile stimulation, modulated by the opioid system. We used a conditioned place preference (CPP) paradigm to test the hedonic dimension of motivation to be cleaned and found that de-parasitized client fish (the butterflyfish Chaetodon auriga) preferred the compartment paired with cleaner fish (Labroides dimidiatus). Treatment with the μ-opioid receptor agonist The µ-opioid receptor agonist 2-Ala-4-mephe-5-gly-enkephalin (DAMGO) dose-dependently increased preference, while treatment with the antagonist naloxone decreased it. To test for fish incentive salience, we used a detour task, with barriers being added after each trial to demand higher response strength to reach the target and found that client fish can circumvent barriers to reach a cleaner-adjacent compartment. Response strength (number of barriers added before 'giving up') was not affected by treatment with either naloxone or DAMGO. Our results show that cleaner-client interactions are hedonically positive for clients, an effect that is mediated by the opiodergic system. Visual contact with cleaners is sufficient to activate incentive salience programmes, but no evidence of participation of the opioidergic system in these programmes was found. Overall, we provide the first evidence confirming the participation of the opioidergic system in motivation to be cleaned in mutualistic associations.

Animals

The opioid receptor-ligand network in human cancers: pan-cancer multi-omics profiling and translational implications.

BACKGROUND: Opioid receptor-ligand signalling has been implicated in tumour biology and perioperative outcomes; however, its pan-cancer molecular landscape and clinical relevance remain incompletely defined. METHODS: We performed a pan-cancer multi-omics analysis of eight predefined opioid receptor-ligand genes across 33 tumour types from The Cancer Genome Atlas. Analyses included gene expression analysis using the linear models for microarray data (limma) package, genomic alterations, DNA methylation, regulatory network inference, pathway activity estimation using gene set variation analysis, and survival modelling. Multivariable Cox regression models were adjusted for age, sex, and tumour stage. RESULTS: Opioid receptor-ligand genes exhibited heterogeneous and generally low-to-moderate expression across tumour types. Genomic and epigenetic alterations were tumour-specific and variably associated with gene expression. Selected genes showed associations with overall survival in a tumour-dependent manner; however, these associations were attenuated after adjustment for clinical covariates and were accompanied by wide confidence intervals in some cohorts. Pathway analyses suggested associations with broader biological programmes, including epithelial-mesenchymal transition and immune-related pathways. Regulatory analyses identified candidate transcription factors and miRNAs, although these findings are exploratory. CONCLUSIONS: This pan-cancer analysis provides a systematic overview of opioid receptor-ligand gene features across human cancers. The observed associations are context-dependent and should be interpreted as hypothesis-generating. Further mechanistic and prospective studies are required to determine the clinical relevance of opioid signalling in cancer and perioperative settings.

Humans

Histochemical localization of opiate receptors and opioid peptides.

It is possible to localize opiate receptors by histochemical methods. They appear in high densities in anatomical areas associated with physiologic functions altered by opiates. They appear to mediate inhibitory responses; some of them, in certain regions could be involved in axo-axonic synapses. The immunohistochemical studies as well as the electrophysiologic results are compatible with the view that the enkephalins are the endogenous substrates for the opiate receptors.

Animals

Involvement of opioid mechanisms in peripheral motor control of detrusor muscle.

Isometric recordings of mechanical activity in muscle strips from rat and human detrusor were performed and the effect of mu- and delta-opioid receptor stimulation and blockade on detrusor contraction induced by electrical field stimulation was tested. Stimulation of the opioid mu-receptor with morphine (10(-13)-10(-4) M) and DAGO (10(-13)-10(-6) M) had no significant effect on electrical field stimulation except at one concentration of morphine (10(-6) M). Naloxone (10(-10)-10(-5) M) caused a significant facilitation of the electrical field stimulation-induced contraction, which was counteracted by morphine (10(-8) M) and the delta-agonist DPDPE (10(-8) M) in both rat and human detrusor. Addition of atropine (10(-6) M) or hexamethonium chloride (10(-6) M) or spantide (10(-6) M) did not alter the facilitating effect of naloxone in the rat detrusor. Hexamethonium (10(-5) M) decreased the facilitating effect of naloxone on electrical field stimulation-induced contractions in the human detrusor, indicating involvement of ganglionic mechanisms. In human detrusor about 15% of the contractile response was found to be atropine-resistant (10(-6) M) and one third of this was found to be resistant to tetrodotoxin (1.5 x 10(-6) M). The atropine resistant-response in human detrusor was facilitated by naloxone to the same extent as the atropine-sensitive part. Adrenergic blockade per se, achieved with phentolamine mesylate (10(-6) M) and propranolol (10(-6) M), caused a significant facilitation of the electrical field stimulation-induced contraction in the rat detrusor but did not affect the facilitating effect of naloxone (10(-13)-10(-5) M).(ABSTRACT TRUNCATED AT 250 WORDS)

Animals

[The cholinoreceptors of the neurons in the edible snail: their identification and plasticity and its regulation by opioids and second messengers].

In the paper is presented the review of author's own data on the cholinoreceptors of identified Helix neurons and the regulation of their plasticity. The review contains the following parts: cholinoreceptors identification, their coupling with ionic channels, identification of opioid receptors, modulation of cholinoreceptors by opioids, plasticity of cholinoreceptors, modulation of their plasticity by the second messengers, second messengers involved in a modulation of cholinoreceptors' plasticity by the opiate kappa-agonist bremazocine.

Animals